Justin "Jay" Bader, MD

2026

• Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma

  Bader JM, Dhiman A, Aguirre N, Ofori KA, Gupta P, Qin H, Sharma A, Mitchell O, Tjota MY, Husain AN, Drazer M, Churpek J, Kindler H, Turaga K. Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma. Npj Precision Oncology 2026 DOI: 10.1038/s41698-026-01495-x.

  Peer-Reviewed Original Research

  This study investigates the prognostic impact of somatic mutations in mesothelioma, showing NF2 truncating variants worsen survival, supporting genomic testing to guide treatment strategies.

  Full Summary

• Peritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance

  Ofori K, Smart H, Liu S, Bader J, Aguirre N, Gupta P, Sharma A, Turaga K. Peritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance. Annals Of Surgical Oncology 2026, 1-4. PMID: 42265516, DOI: 10.1245/s10434-026-19903-8.

  Peer-Reviewed Original Research

  This study investigates the limitations of circulating tumor DNA (ctDNA) surveillance in stage II–III colon cancer, showing reduced detection of isolated peritoneal metastases due to biological constraints.

  Full Summary

• Natural history, treatment, survival, and causes of mortality in patients with subsolid and ground-glass nodules

  Bader J, Prince S, de Santis W, Kane E, Tanoue L, Bader A, Blasberg J, Detterbeck F, Woodard G. Natural history, treatment, survival, and causes of mortality in patients with subsolid and ground-glass nodules. Chest 2026 PMID: 42155700, DOI: 10.1016/j.chest.2026.04.053.

  Peer-Reviewed Original Research

  Altmetric

• Radiographic Tumor Regression as a Predictor for Pathologic Response after Neoadjuvant Therapy for Non-Small Cell Lung Cancer

  Bader J, Ermer T, de Santis W, Ragoowansi H, Kramer R, Zolfaghari E, Tremblay E, Resio B, Boffa D, Blasberg J, Bader A, Dacic S, Woodard G. Radiographic Tumor Regression as a Predictor for Pathologic Response after Neoadjuvant Therapy for Non-Small Cell Lung Cancer. JTCVS Open 2026, 101831. DOI: 10.1016/j.xjon.2026.101831.

  Peer-Reviewed Original Research

  Altmetric

• CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma

  Bader J, de Santis W, Kane E, Jaiswal A, Cho C, Kidacki M, Chen L, Dacic S, Woodard G. CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma. Translational Lung Cancer Research 2026, 15: 131-131. PMID: 42291360, PMCID: PMC13263804, DOI: 10.21037/tlcr-2026-1-0102.

  Peer-Reviewed Original Research

• Evolving therapeutics in colorectal cancer peritoneal metastases

  Bader J, Aguirre N, Schultz K, Ofori K, Godfrey E, Gupta P, Tseng R, Cecchini M, Sundar R, Turaga K. Evolving therapeutics in colorectal cancer peritoneal metastases. Cancer And Metastasis Reviews 2026, 45: 25. PMID: 42024175, DOI: 10.1007/s10555-026-10335-0.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  MeSH Keywords

• ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases

  Gupta P, Godfrey E, Schultz K, Qiao L, Aguirre N, Bader J, Foote M, Shen J, Shergill A, Cecchini M, Sundar R, Sheltzer J, Turaga K. ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal Metastases. Annals Of Surgical Oncology 2026, 33: 6194-6195. PMID: 41896510, DOI: 10.1245/s10434-026-19312-x.

  Peer-Reviewed Original Research

• PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma

  Gupta P, Gujarathi R, Qiao L, Godfrey E, Schultz K, Butensky S, Bader J, Sundar R, Cecchini M, Shergill A, Sheltzer J, Turaga K. PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma. JCO Precision Oncology 2026, 10: e2500741. PMID: 41712872, DOI: 10.1200/po-25-00741.

  Peer-Reviewed Original Research

  This study investigates PIK3CA mutations in early-onset appendiceal adenocarcinoma, showing their higher prevalence and association with worse survival, suggesting potential for targeted therapies.

  Full Summary

• Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases

  Gupta P, Godfrey E, Schultz K, Qiao L, Aguirre N, Bader J, Foote M, Shen J, Shergill A, Cecchini M, Sundar R, Sheltzer J, Turaga K. Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases. Annals Of Surgical Oncology 2026, 33: 6140-6145. PMID: 41634518, DOI: 10.1245/s10434-025-19057-z.

  Peer-Reviewed Original Research

  This study investigates drug sensitivity in colorectal cancer peritoneal metastases, showing CMS4 tumors respond better to mitomycin-C and irinotecan, informing personalized chemotherapy strategies.

  Full Summary

• Deep learning approach for critical exposure during division of the inferior mesenteric artery in colorectal surgery

  Bader J, Sun X, Rosenfelt T, Ramirez-Hardy A, Vitchutripop T, Srinivasan A, Pantel H, Khanna A, Rakita D. Deep learning approach for critical exposure during division of the inferior mesenteric artery in colorectal surgery. Journal Of Robotic Surgery 2026, 20: 155. PMID: 41486401, DOI: 10.1007/s11701-025-03121-7.

  Peer-Reviewed Original Research

  Citations